Beam Therapeutics Inc.

Clinical research activity is centered on alpha-1 antitrypsin deficiency with emphasis on its impact on lung disease and liver disease in adults. The sponsor’s trial portfolio in this area reflects a focused interest in disorders arising from abnormal protein handling and downstream tissue injury.

• AATD-associated lung disease
• AATD-associated liver disease
• Adult respiratory disease
• Hepatic disease

Research in this field is directed toward understanding disease-related biological activity and therapeutic effects in both pulmonary and hepatic manifestations.